Comparative Pharmacology
Head-to-head clinical analysis: BROMPHERIL versus FAYOSIM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHERIL versus FAYOSIM.
BROMPHERIL vs FAYOSIM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brompheril is a mu-opioid receptor agonist with additional sigma-1 receptor antagonism, producing analgesic effects and modulating neuropathic pain.
FAYOSIM (plecanatide) is a guanylate cyclase-C (GC-C) agonist. It binds to GC-C receptors on the luminal surface of intestinal epithelial cells, activating the receptor and increasing intracellular cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP stimulates chloride and bicarbonate secretion into the intestinal lumen, enhancing fluid secretion and accelerating gastrointestinal transit, thereby promoting bowel movements.
In adults, the usual dose is 1-2 mg/kg intravenously every 4-6 hours as needed. Alternatively, 5 mg can be administered intramuscularly or subcutaneously every 4 hours.
10 mg orally once daily
None Documented
None Documented
Terminal half-life 2.5-4 hours; prolonged in renal impairment (up to 12 hours in severe cases).
12-16 hours in healthy adults; prolonged to 20-30 hours in moderate renal impairment (CrCl <50 mL/min) requiring dose adjustment.
Primarily renal (60-70% as unchanged drug); 15-20% fecal via biliary elimination; minor metabolic clearance.
Primarily renal elimination, 80% unchanged drug in urine; 15% biliary/fecal; 5% metabolized.
Category C
Category C
Antihistamine
Antihistamine